| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 62.86 | -0.08 (-0.13%) | 49.79 - 66.06 | 71.8 thousand (Below Avg) |
Market data as of 9:47AM 06/19/13. Quotes are delayed by at least 15 min.
| Open | 63.06 |
|---|---|
| Previous Close | 62.94 |
| Day's Range | 62.72 - 63.11 |
| Market Cap | 51.4B |
| Avg Volume (10 Day) | 4.0M |
| Price/Earnings (Trailing 12 Mo.) | 36.0x |
| Earnings Per Share (Trailing 12 Mo.) | 1.75 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Pass |
| Sells at 25% discount to intrinsic value? | Pass |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Express Scripts to Present at the William Blair 33rd Annual Growth Stock Conference
PR Newswire - Thursday 06/06/2013 4:18 PM ET
U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015
PR Newswire - Tuesday 05/21/2013 8:00 AM ET
| ESRX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 128.53% | |
| Net Income Growth (1yr) | 20.10% | |
| Total Debt/Equity | 0.61 | |
| LT Debt/Equity | 0.58 | |
| Earnings Yield | 2.78% | |
| Price/Sales | 0.48 |
| Company | Last | Change |
|---|---|---|
| UnitedHealth Group Inc | 65.85 | +0.26% |
| WellPoint Inc | 79.20 | -0.55% |
| Aetna Inc | 62.45 | -0.32% |
| Cigna Corp | 69.59 | -0.10% |
| Humana Inc | 83.77 | +0.20% |
Data is delayed by at least 15 min.